在线轻松预约，无需出国即可与美国医生“面对面”视频交流，获取权威专业的第二诊疗意见和方案！登录好医友官网查询更多美国医生信息（咨询热线4008860922）
【执业认证】
美国内科医学委员会——内科学医师资格认证
美国内科医学委员会——内科肿瘤学医师资格认证
【医疗专长】
迈克尔·卡斯特罗（Michael Castro）博士，毕业于美国哥伦比亚大学医学院，深耕于肿瘤内科治疗领域二十余年。临床擅长进行癌症的免疫治疗和精准医疗，即使用基因检测和生物标记物，根据不同的肿瘤代谢和易感性，为癌症患者制定更有效、毒性更小的精准治疗方案。卡斯特罗博士可提供全面的肿瘤医疗方案，包括癌症精准医疗、辅助疗法、终末期治疗、姑息疗法、以及癌症预防、遗传性筛查与检测等。他的诊疗范围涵盖多种恶性实体肿瘤，专精于胃癌、结直肠癌、食管癌、胰腺癌、肝胆肿瘤等消化系统实体肿瘤的个性化诊治。
迄今卡斯特罗博士已经撰写并发表了超过30多篇的同行评议文章。自2011年以来，卡斯特罗一直被《美国新闻和世界报道》（US News and World Report）评选为美国顶级医生之一，被美国檀香山杂志评选为夏威夷最顶尖的医生之一（Hawaii’s Top Doctors）。
【教育背景】
医学院：哥伦比亚大学内科与外科学院（Columbia University College of Physicians & Surgeons），获得医学博士学位；
实习/住院医师训练： St Luke's-罗斯福医疗中心（St Luke's-Roosevelt Hospital Center）内科实习和住院医师培训；
专科临床培训：西奈山赫斯科学和医学中心（Mt Sinai SOM）血液学和肿瘤学专科临床培训，；
进阶培训：MD安德森癌症中心（MD Anderson Cancer Center）高剂量白细胞介素2培训。
【荣誉与奖项】
▪ 2015年、2016年，获得由《新闻周刊》（Newsweek）评选的“美国顶尖医生”荣誉称号（Top Doctors in America）；
▪ 2014-2016年，获得由《檀香山杂志》（Honolulu Magazine）评选的“檀香山顶尖医生“荣誉称号（Top Doctors in Honolulu）；
▪ 2013年，获得“CMS Stage 1 HER”荣誉；
▪ 2011年，获得由《美国新闻与世界报道》（US NEWS AND WORLD REPORT）CASTLE CONNOLLY评选的“美国顶尖医生”荣誉称号（TOP DOCTORS IN AMERICA）
【出版物摘选】
杂志论文：
Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinom... Castro MP and Goldstein N, Journal for ImmunoTherapy of Cancer, 12/15/2015
Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with... Michael P. Castro, Bradford P. Whitcomb, Deborah A. Zajchowski, and Robert L. Coleman, Gynecologic Oncology Research and Practice 2015, 2:4, 8/28/2015
Metastatic Cancer of Cowper's Gland: A Rare Cancer Managed Successfully by Molecular Profiling. Myers CE, Gatalica Z, Spinelli A, Castro M, Linden E, Sartor O, Sargent M., Case Rep Oncol. 2014 Jan 16;7(1):52-7., 2014
Apocrine carcinoma of the breast: a comprehensive review. Vranic S, Schmitt F, Sapino A, Costa JL, Reddy S, Castro M, Gatalica Z., Histol Histopathol. 2013 Nov;28(11):1393-409. Epub 2013 Jun 17., 6/13/2013
Peripheral sensory neuropathy—fighting cold with cold M. Castro, Lancet Oncology Volume 9, No. 5, p415–416, May 2008, 2008
Pharmacogenetics in the clinic: new questions about tamoxifen M. Castro, J Oncol Prac 2006 2:100, 1/1/2006
Thymidine reduce: an antidote for pemetrexed related toxicity in the setting of acute renal failure Michael Castro, J Clin Oncol 2003, 21:4066, 1/1/2003
Cerebrospinal fluid gastrin releasing peptide in the diagnosis of leptomeningeal metastases from small cell carcinoma Michael P. Castro M.D., Tom J. McDonald M.D., Stephen J. Qualman M.D. andThomas M. Odorisio M.D., Cancer Volume 91, Issue 11, pages 2122–2126, 1 June 2001, 5/31/2001
Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature M P Castro, J Vanauken P, Spencer-CisekS, LeghaR, W Sponzo, Cancer 1999 Vol 85 (1055-1059), 1999
Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report MP Castro, Fodor L, Orlandi L, Cancer 1998 Vol 82 (639-641), 1/1/1998
书籍或图书章节
Heme-Onc Secrets Chapter: Targeted Therapy
Michael Castro
Editors: M. WOOD.UNIVERSITY OF VERMONT PRESS, Burlington
2003
摘要或海报
Drug efflux pump expression in 50,000 molecularly-profiled cancer patients. Rebecca Feldman, Brian L. Abbott, Sandeep K. Reddy, Michael Castro, J Clin Oncol 33, 2015 (suppl; abstr 11108), 2015 ASCO Annual Meeting, 6/2015
Expression patterns of a taxane sensitivity panel in 25,000 cancer patients. Brian L. Abbott, Rebecca Feldman, Sandeep K. Reddy, Michael Castro, J Clin Oncol 33, 2015 (suppl; abstr e22235), 2015 ASCO Annual Meeting, 6/2015
Potential impact of different methodologies for detecting EGFR mutations in selecting chemotherapy for patients with lung cancer. Ryan P. Bender, Anatole Ghazalpour, Zheng Tan, Zoran Gatalica, Les Paul, Sandeep K. Reddy, Michael Castro, J Clin Oncol 31, 2013 (suppl; abstr e19006), 2013 ASCO Annual Meeting, 6/2013
Biomarker analysis of glioblastoma and potential implications for therapy. Joanne Xiu, Rebecca Anne Feldman-Moreno, David Arguello, Zoran Gatalica, Anatole Ghazalpour, Ryan P. Bender, Michael Castro, Sandeep K. Reddy, Gargi Dan Basu, Les Paul, J Clin Oncol 31, 2013 (suppl; abstr 2041), 2013 ASCO Annual Meeting, 6/2013
Pharmacokinetics of BSI-201, A poly (ADP-ribose) polymerase-1 (PARP1) inhibitor in cerebrospinal fluid of a breast cancer patient with carcinomatous meningitis. M Castro, L Li, TE Stallings., PROC AM SOC CLIN ONCOL 2010, ABSTRACT 48374, ASCO Annual Meeting 2010, 6/2010
Pharmacogenetic correlates of benefit from gemcitabine and platinum in patients with advanced bladder cancer. M CASTRO, A NEUMANN, M KONICHEXKY, K DANNENBERG, S STEMMER, PROC AM SOC CLIN ONCOL 2004 ABSTRACT 3203, ASCO Annual Meeting 2004, 6/1/2004
Successful use of anti-CD20 monoclonal antibody, Rituxan, in patients with non-Hodgkins lymphoma and renal insufficiency CASTRO MP, VANAUKEN J, SPONZO RW., AM SOC CLIN ONCOL 2001, 20:3325., ASCO Annual Meeting 2001, 6/1/2001
Impact of risk stratification on mammographic interpretation. R SPONZO, T ASHIKAGA, C HOWLAND, P CISEK, MP CASTRO, PROC AM SOC CLIN ONCOL 2000, 19:335., ASCO Annual Meeting 2000, 6/1/2000
讲座
Personalized Medicine in Oncology: Recent Updates
其他
TIMING IS EVERYTHING OR COULD BE. M. Castro, J CLIN ONCOL 21: 755, 2003.
https://hwmaint.jco.ascopubs.org/cgi/content/full/21/4/755-a
2003
THE SIMPLETON’S ERROR IN DRUG DEVELOPMENT. M. Castro, J CLIN ONCOL 2002 20: 4606-7.
https://jco.ascopubs.org/content/20/23/4606
